| 2.44 0.02 (0.83%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.2  |
1-year : | 3.73 |
| Resists | First : | 2.74 |
Second : | 3.2 |
| Pivot price | 2.22 |
|||
| Supports | First : | 2.17 |
Second : | 1.82 |
| MAs | MA(5) : | 2.44 |
MA(20) : | 2.26  |
| MA(100) : | 2.73 |
MA(250) : | 6.09 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 79.8 |
D(3) : | 85.3 |
| RSI | RSI(14): 55.8 |
|||
| 52-week | High : | 17.25 | Low : | 1.7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ATOS ] has closed below upper band by 23.0%. Bollinger Bands are 30.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.74 - 2.76 | 2.76 - 2.77 |
| Low: | 2.09 - 2.11 | 2.11 - 2.12 |
| Close: | 2.42 - 2.44 | 2.44 - 2.46 |
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Wed, 07 Oct 2026
Atossa Therapeutics Inc Share Price - ATOS, RNS News, Articles, Quotes, & Charts (NASDAQ:ATOS) - Proactive financial news
Tue, 29 Sep 2026
Atossa Therapeutics, Inc. (ATOS) Plans CVR Paying Up To $50M From Potential PRV - TradingView
Tue, 29 Sep 2026
Atossa Plans $50M-Capped CVR for Voucher Proceeds | ATOS Stock News - Stock Titan
Thu, 24 Sep 2026
Harvard panel will explore turning aging research into new treatments - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 13.6 (%) |
| Shares Short | 788 (K) |
| Shares Short P.Month | 756 (K) |
| EPS | -4.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -50.7 % |
| Return on Equity (ttm) | -89.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.55 |
| PEG Ratio | 0 |
| Price to Book value | 0.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|